Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Boilerplate incorporation language for the Company’s Regulation FD disclosure.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate incorporation language for the Company’s Regulation FD disclosure
- No substantive operating, financial, or investor-impacting information in the provided excerpt
Item EX-99.1 · Exhibit EX-99.2
- ARCT-810 Phase 2 interim data showed favorable safety and improved ammonia and glutamine biomarkers, supporting continued clinical development
- LUNAR 2.0 delivered 40-fold higher hEPO expression and 38-fold higher hOTC potency than comparators in NHP studies
- ARCT-2601 expected to enter the ongoing Phase 2 study near year-end 2026, potentially enabling lower or less frequent dosing
- FDA feedback supports integrating ARCT-2601 into the OTC deficiency trial, but clinical benefit remains unproven
- Planned October acquisition of myNEO adds AI capabilities for mRNA design and target identification, expanding platform development potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.